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Abstract
Tumor necrosis factor-alpha (TNF) is one of a number of systemic and immunomodulating
cytokines that generally act to promote acute-phase reactions but can drive degenerative changes
when chronically elevated. Traditional focus on TNF has been directed at these inflammation-
related functions. Of particular relevance to intersections between neuroinflammation and
neurodegeneration is the ability of TNF to increase expression of interleukin-1 (IL-1), which in turn
increases production of the precursors necessary for formation of amyloid plaques, neurofibrillary
tangles, and Lewy bodies. More recent data have revealed that TNF, one of the few
gliotransmitters, has strikingly acute effects on synaptic physiology. These complex influences on
neural health suggest that manipulation of this cytokine might have important impacts on diseases
characterized by glial activation, cytokine-mediated neuroinflammation, and synaptic dysfunction.
Toward such manipulation in Alzheimer's disease, a six-month study was conducted with 15
probable-Alzheimer patients who were treated weekly with perispinal injection of Etanercept, an
FDA-approved TNF inhibitor that is now widely used for treatment of rheumatoid arthritis and
other systemic diseases associated with inflammation. The results demonstrated that perispinal
administration of etanercept could provide sustained improvement in cognitive function for
Alzheimer patients. Additionally, the authors were impressed by the striking rapidity with which
these improvements occurred in the study patients. An example of this rapid improvement is
presented in this issue as a case report by Tobinick and Gross. Such rapid gain of function inspires
speculation about the role of gliotransmission or other equally rapid synaptic events in the
relationship of TNF to Alzheimer-impacted neurophysiology. Because of the inability of large
molecules such as etanercept to cross the blood brain barrier following conventional systemic
administration, it is likely that the more direct drug delivery system pioneered by Tobinick also
contributed to the effectiveness of the treatment. If so, this system could be useful in drug delivery
to the brain in other neural disorders, as well as in animal research studies, many of which currently
employ delivery strategies that inflict damage to neural cells and thus engender neuroinflammatory
responses.
Introduction
The Tobinick and Gross case report in this issue of the
Journal of Neuroinflammation [1] is hopefully the first of
many articles attesting to the benefit of direct-to-the-brain
delivery of anti-cytokine therapies, which may result in
rapid and sustained improvement in cognition, behavior,
and attentiveness. In view of the discouraging results to
date of trials testing the efficacy of anti-inflammatory
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treatments and vaccines directed against A-beta, together
with the mounting numbers of new Alzheimer cases each
year, the results shown in the case report in this issue and
those from previous reports by Tobinick and colleagues
[2-4] are indeed welcome. On the clinical research side,
these findings call for clinical trials to more completely
characterize the efficacy of etanercept treatment and the
appropriateness of the delivery system; and on the basic
research side, they underscore the need for a clearer pic-
ture of the functions of neural cytokines, in particular
studies to pinpoint the basic mechanisms underlying not
only this rapid recovery of functions but also the underly-
ing principles responsible for maintenance of these func-
tions over months, even years, which these authors report
for perispinal treatment with etanercept.
Background
The rapidity with which cognitive and behavioral func-
tions are recovered by the patient described in a case
report in this issue by Tobinick and Gross is consistent
with the idea that perispinal etanercept treatment modu-
lates synaptic function. It is tempting to suppose that this
rapid recovery of function is a consequence of etanercept
capture of excess glia-derived TNF, which results in
reversal of synaptic dysregulation. TNF has been described
in experimental studies as a gliotransmitter involved in
modulation of synapses [5-7] and of long term potentia-
tion and memory functions [8,9]. Interestingly, TNF
knockout mice show increased performance in the Morris
water-maze test of spatial memory [10,11], and overex-
pression of TNF is associated with impairment in the same
task [11]. Thus, detrimental consequences are to be
expected in the case of TNF elevation under conditions of
neuroinflammation, of which Alzheimer's disease is but
one example. Moreover, titration of these TNF levels back
to the normal range by a tool such as perispinal etanercept
is a logical approach for effecting cognitive recovery. By
analogy, other proinflammatory cytokines that have been
shown to interfere with LTP and related behaviors, such as
IL-1 [12,13], might be amenable to similarly beneficial
manipulations.
It is also worth noting that while this case report empha-
sizes the rapidity of the response to etanercept, its effects
are also relatively long-lasting [3], suggesting involvement
of mechanisms that are more classically anti-inflamma-
tory. It is even possible that they involve activity beyond
the TNF-binding activity of etanercept. The drug is actu-
ally a fusion protein comprising domains from a TNF
receptor fused to the Fc portion of IgG1. Passive immuni-
zation is one of the intriguing developments in prospec-
tive AD treatments; and while the preclinical studies and
current Phase III trials have focused on delivery of anti-
bodies that are specifically reactive with amyloid beta-
peptide (Abeta), it appears that any immunization that
generates a strong humoral response can facilitate the
clearance of Abeta plaques in APP-transgenic mice [14].
Anti-inflammatory effects of certain Fc receptor ligands
are well established [15], suggesting that etanercept treat-
ment may have a generalized effect on the immune system
due to Fc receptor ligation. Calculations, based on stoichi-
ometry of binding and clearance, suggest the possibility
that the effects of anti-Abeta antibodies result from such
an antigen-independent mechanism [16]. Exploration of
the functional consequences of the Fc fusion domain in
etanercept might reveal this agent to be a combination
anti-TNF/"passive immunization" therapy.
Commentator observations
In this section, my comments reflect my own thoughts on
this treatment strategy and my own experiences in viewing
it, and are accompanied by a few of my own remarks
directed toward the necessity of giving attention to this
novel treatment. I first became aware of this treatment
when a reporter from The Los Angeles Times contacted me
in 2006 for a comment on an article he was writing on a
novel and successful Alzheimer treatment trial. Although
my interest was piqued by this, it was only more recently
when Dr. Tobinick contacted me and sent a preprint of the
findings discussed in the Times [3] that I decided to go and
see for myself the treatment and talk to the patients and
family members. I called the day before, and was invited
to visit the next day, November 7, 2007. Each of the three
patients I saw treated had been tested and diagnosed with
probable Alzheimer's disease by a neurologist before per-
ispinal etanercept treatment had begun. They and their
families invited me to be present during the treatment and
in the interviews before and after. I noticed clinical
improvement in each of the three patients within minutes
following treatment. My first impression was that there
was a clear, easily discernible, difference in each. They
were more cheerful, more at ease, and more attentive. My
impressions were the same as those shared by each of the
families (please see the movie for example). This rapid
turn around brought to mind the first time, now almost
two decades ago[17], that I was the original witness to the
remarkable overexpression of immune cytokines in acti-
vated glia in Alzheimer patients and even in fetuses and
neonates with Down's syndrome – I was amazed!
Conclusion
The most important outcome of this case, in the mind of
the commentator, is that we endeavor to reduce the bias
that is inherent and important in scientific thinking, but
which, unfortunately, can impede timely consideration of
new scientific approaches. Recognition of the role of
cytokines in the pathogenesis of Alzheimer's disease pro-
vided a new paradigm for the Alzheimer research commu-
nity [18]. And now, the therapeutic intervention in this
case report provides a new approach to regulation of thePublish with BioMed Central    and   every 
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role that cytokines play in pathogenesis. In view of this,
constructive scientific approaches to examine and further
investigate the beneficial results reported for perispinal
etanercept treatment should be undertaken. Taking
advantage of what we have learned in the past will allow
for synthesis of new hypotheses toward our common goal
of solving the riddle of Alzheimer's disease. Such efforts
are imperative for the millions who suffer, for their fami-
lies, and for the social and economic health of our society.
As pointed out dramatically by Andrew Grove in a speech
at the meeting of the Society for Neuroscience this year, a
new and more productive approach to researching, dis-
covering, and bringing to the public the news of effective
treatments for neurodegenerative diseases is long over-
due. This case report is published in an effort to broaden
the spectrum of such potential treatment strategies for
Alzheimer's disease, and for other diseases mediated by
cytokines. Hopefully, our efforts will be supported by
rapid allocation of the resources necessary for both basic
and clinical scientific investigations that will answer Mr.
Grove's revolutionary challenge.
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